CRISPR Therapeutics AG Profit Margin

The latest profit margin for CRSP is -13856.54% as of March 2026. That compares with -1067.74% in the prior-year period — down 1197.7% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside CRISPR Therapeutics AG's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRSP's profit margin moved from -1067.74% to -13856.54% — a 1197.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CRISPR Therapeutics AG's valuation or profitability profile.

Against Healthcare companies, CRSP currently prints -13856.54% for profit margin, while the sector average sits near 15.29%. That is roughly 90707.8% below the sector mean. Large gaps often invite a closer look at CRISPR Therapeutics AG's growth, margins, and balance sheet.

Profit Margin shows how effectively CRISPR Therapeutics AG converts resources into returns. At -13856.54%, CRSP may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1067.74% in the prior-year period — down 1197.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRSP's profit margin (-13856.54%), review year-over-year change from -1067.74%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.